7 days ago
BCRX
AnalystsJonathan WollebenJonathan Wolleben's Stock Forecasts
AnalystsJonathan Wolleben
Analyst Ranking
Top 4%
#184 out of 5071 analysts
Average Return
+15.9%
Win Rate
51%115 out of 224
Risk vs Reward
Poor
Good
Jonathan Wolleben's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Madrigal Pharmaceuticals IncMDGL | +365.01% | $64.44 | $299.65 | 2022-05-10 - 2023-05-09 | Buy |
Dbv Technologies SaDBVT | +362.90% | $3.45 | $15.97 | 2024-12-10 - 2025-10-21 | Buy |
Dbv Technologies SaDBVT | +271.40% | $4.30 | $15.97 | 2025-03-04 - 2025-10-21 | Buy |
Dbv Technologies SaDBVT | +221.33% | $4.97 | $15.97 | 2025-01-10 - 2025-10-21 | Buy |
Sagimet Biosciences IncSGMT | +214.13% | $2.76 | $8.67 | 2024-08-15 - 2025-08-14 | Buy |
Jonathan Wolleben Analyst Color
Get additional color on Jonathan Wolleben's coverage of popular stocks
a year ago
SPOT
Jonathan Wolleben's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Biocryst Pharmaceuticals IncBCRX | 9 | Buy | $27.00 | +286.54% | Maintains | 7 days ago |
Ocular Therapeutix IncOCUL | 16 | Buy | $29.00 | +146.39% | Maintains | 21 days ago |
Crinetics Pharmaceuticals IncCRNX | 16 | Buy | $143.00 | +233.72% | Maintains | a month ago |
Rhythm Pharmaceuticals IncRYTM | 5 | Buy | $142.00 | +32.52% | Maintains | a month ago |
Kalvista Pharmaceuticals IncKALV | 5 | Buy | $28.00 | +144.97% | Maintains | a month ago |
Madrigal Pharmaceuticals IncMDGL | 11 | Buy | $485.00 | +12.79% | Maintains | 2 months ago |
Larimar Therapeutics IncLRMR | 13 | Buy | $18.00 | +319.58% | Reiterates | 2 months ago |
Pharvaris NvPHVS | 12 | Buy | $52.00 | +116.76% | Maintains | 2 months ago |
Astria Therapeutics IncATXS | 3 | Buy | $26.00 | +113.82% | Maintains | 2 months ago |
Quince Therapeutics IncQNCX | 2 | Buy | $8.00 | +339.56% | Maintains | 2 months ago |
Protagonist Therapeutics IncPTGX | 12 | Buy | $69.00 | -8.00% | Maintains | 2 months ago |
Mirum Pharmaceuticals IncMIRM | 11 | Buy | $81.00 | +17.43% | Maintains | 2 months ago |
Structure Therapeutics IncGPCR | 10 | Buy | $87.00 | +223.18% | Maintains | 2 months ago |
Altimmune IncALT | 12 | Buy | $15.00 | +271.29% | Maintains | 3 months ago |
Proqr Therapeutics NvPRQR | 6 | Buy | $8.00 | +171.19% | Reiterates | 4 months ago |
Dbv Technologies SaDBVT | 15 | Buy | $21.00 | +31.50% | Reiterates | 4 months ago |
Skye Bioscience IncSKYE | 3 | Buy | $15.00 | +934.48% | Reiterates | 4 months ago |
Aura Biosciences IncAURA | 9 | Buy | $19.00 | +210.46% | Reiterates | 5 months ago |
Clearside Biomedical IncCLSD | 11 | Buy | $75.00 | +1,810.83% | Reiterates | 5 months ago |
Mbx Biosciences IncMBX | 1 | Buy | $38.00 | +148.20% | Initiates Coverage On | 6 months ago |
Savara IncSVRA | 8 | Buy | $9.00 | +112.77% | Reiterates | 10 months ago |
Hilton Grand Vacations IncHGV | 1 | Buy | $50.00 | +14.21% | Maintains | 10 months ago |
Costar Group IncCSGP | 1 | Buy | $90.00 | +17.11% | Reiterates | 10 months ago |
Spruce Biosciences IncSPRB | 7 | Hold | $3.00 | -97.68% | Downgrades | 10 months ago |
Spotify Technology SaSPOT | 1 | Buy | $485.00 | -29.63% | Downgrades | a year ago |
Allakos IncALLK | 6 | Buy | $3.00 | N/A | Reiterates | a year ago |
Sagimet Biosciences IncSGMT | 8 | Buy | $32.00 | N/A | Maintains | a year ago |
Rallybio CorpRLYB | 11 | Buy | $8.00 | N/A | Reiterates | 2 years ago |
Warner Music Group CorpWMG | 1 | Buy | $24.00 | N/A | Maintains | 2 years ago |
Strongbridge Biopharma PLCSBBP | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.